GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Earnings Yield (Joel Greenblatt) %

Vectus Biosystems (ASX:VBS) Earnings Yield (Joel Greenblatt) % : 0.00% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems Earnings Yield (Joel Greenblatt) %?

Vectus Biosystems's Enterprise Value for the quarter that ended in Dec. 2023 was A$13.94 Mil. Vectus Biosystems's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-2.48 Mil. Vectus Biosystems's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Vectus Biosystems's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

ASX:VBS' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -65.77   Med: 0   Max: 0
Current: -61.35

ASX:VBS's Earnings Yield (Joel Greenblatt) % is ranked worse than
78.02% of 1415 companies
in the Biotechnology industry
Industry Median: -15.62 vs ASX:VBS: -61.35

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Vectus Biosystems's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Vectus Biosystems Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Vectus Biosystems's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Earnings Yield (Joel Greenblatt) % Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial -24.04 -12.36 -8.34 -8.16 -15.80

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -8.16 - -15.80 -

Competitive Comparison of Vectus Biosystems's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Vectus Biosystems's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vectus Biosystems's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's Earnings Yield (Joel Greenblatt) % falls into.



Vectus Biosystems Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Vectus Biosystemss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Jun. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-3.243/20.52238
=-15.80 %

For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.



Vectus Biosystems  (ASX:VBS) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Vectus Biosystems Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectus Biosystems (ASX:VBS) Business Description

Industry
Traded in Other Exchanges
N/A
Address
3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines